List of Excipients in Branded Drug VFEND

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Roerig	VFEND	voriconazole	0049-3170	CROSCARMELLOSE SODIUM
Roerig	VFEND	voriconazole	0049-3170	HYPROMELLOSE
Roerig	VFEND	voriconazole	0049-3170	LACTOSE MONOHYDRATE
Roerig	VFEND	voriconazole	0049-3170	MAGNESIUM STEARATE
Roerig	VFEND	voriconazole	0049-3170	POVIDONE

VFEND Excipient Strategy and Commercial Opportunities for Voriconazole

Last updated: August 26, 2026

VFEND is Pfizer’s branded voriconazole product, an extended-spectrum triazole antifungal marketed in intravenous, tablet, and oral-suspension forms. The strongest commercial opportunities are in excipient-led reformulation: renal-safer intravenous delivery, improved pediatric acceptability, simplified oral dosing, lower-cost manufacturing, and dosage forms that reduce variability in patients receiving therapeutic drug monitoring.

What formulations does VFEND use?

VFEND is approved in three principal presentations in the United States:

Presentation	Strength or concentration	Primary excipient strategy	Commercial relevance
Tablets	50 mg and 200 mg	Conventional lactose-starch direct-compression or granulation platform	Lowest-cost generic and hospital formulary opportunity
Oral suspension	40 mg/mL after reconstitution	Sucrose-based powder with suspending, buffering, flavoring, and preservation system	Pediatric and dysphagic-patient differentiation
Intravenous injection	200 mg vial, reconstituted and diluted before infusion	Sulfobutyl ether beta-cyclodextrin sodium, or SBECD, as solubilizer	High-value reformulation opportunity because of renal limitations

The reference product’s oral dosage forms rely on conventional excipients. The intravenous formulation depends on SBECD to solubilize voriconazole, which has poor aqueous solubility. This excipient choice is clinically important because SBECD exposure increases in patients with reduced renal function.

What excipients are used in VFEND tablets?

The US prescribing information identifies lactose monohydrate, pregelatinized starch, croscarmellose sodium, povidone, and magnesium stearate as inactive ingredients in VFEND tablets.[1]

Their functional roles are conventional:

• Lactose monohydrate is a diluent.
• Pregelatinized starch supports binding and disintegration.
• Croscarmellose sodium promotes tablet breakup.
• Povidone acts as a binder.
• Magnesium stearate reduces tooling friction during compression.

This composition provides a relatively accessible generic platform. The formulation does not depend on a complex lipid system, amorphous solid dispersion, specialized coating technology, or controlled-release polymer matrix.

What excipients are used in the VFEND oral suspension?

VFEND powder for oral suspension contains a high-sucrose vehicle with colloidal silicon dioxide, titanium dioxide, xanthan gum, sodium citrate, citric acid, sodium benzoate, and flavoring components.[1]

The formulation addresses several technical requirements:

• Xanthan gum provides suspension viscosity.
• Colloidal silicon dioxide improves powder handling and may support suspension structure.
• Sodium citrate and citric acid provide buffering.
• Sodium benzoate provides antimicrobial preservation.
• Sucrose improves palatability and contributes to viscosity.
• Flavoring reduces the bitterness associated with voriconazole.

The suspension is reconstituted to 40 mg/mL. This concentration supports weight-based pediatric dosing but creates a narrow margin for dosing errors because small volume deviations can materially change exposure.

Why does VFEND intravenous formulation use SBECD?

Voriconazole has limited water solubility. SBECD forms an inclusion complex with the active ingredient and enables an injectable formulation suitable for intravenous infusion.

The commercial tradeoff is renal exposure. SBECD is predominantly eliminated by the kidneys and can accumulate in patients with impaired renal function. The VFEND label advises against use of the intravenous formulation in patients with creatinine clearance below 50 mL/min unless the benefit outweighs the risk.[1]

This limitation creates the clearest excipient-driven commercial opening in the VFEND franchise.

Which excipient characteristics create commercial opportunities?

The most valuable opportunities are linked to clinical constraints, not simple substitution of inactive ingredients.

Renal-safer intravenous voriconazole

A next-generation injectable product could seek to reduce or eliminate SBECD while maintaining:

• Equivalent or improved voriconazole solubility.
• Stable concentration during dilution.
• Acceptable infusion compatibility.
• Low particulate generation.
• Chemical stability over the labeled shelf life.
• Compatibility with common hospital infusion fluids.
• A manageable manufacturing process.

Potential solubilization platforms include alternative cyclodextrins, cosolvent systems, surfactant systems, lipid-based dispersions, nanosuspensions, and amorphous or crystalline particle engineering. Each platform introduces a different regulatory and manufacturing burden.

A lower-SBECD or SBECD-free formulation could target patients with acute kidney injury, chronic kidney disease, renal replacement therapy, or intensive-care exposure. This would be a clinical positioning strategy rather than a simple generic substitution.

Pediatric palatability

The oral suspension is an important commercial segment because voriconazole is used in children for serious invasive fungal infections, including infections caused by Aspergillus and certain rare molds. Pediatric dosing is weight based, and treatment can continue for extended periods.

Commercially relevant improvements include:

• Reduced bitterness.
• Lower sucrose content.
• Better pourability after reconstitution.
• Reduced sedimentation and caking.
• Longer in-use stability.
• More accurate dosing with an oral syringe.
• A lower concentration for very small children.
• A higher concentration to reduce administration volume in adolescents.

Taste masking may use ion-exchange resins, polymeric coatings, cyclodextrin complexes, lipid particles, or pH-managed flavor systems. The formulation must preserve rapid and predictable release because voriconazole exposure is highly variable and routinely managed with therapeutic drug monitoring.

Low-sugar and diabetic-friendly formulations

VFEND oral suspension contains sucrose. A sugar-reduced or sugar-free product could address patients with diabetes, prolonged treatment courses, dental-risk concerns, or dietary restrictions.

Replacing sucrose is technically difficult because sucrose affects more than taste. It contributes to bulk, mouthfeel, viscosity, powder density, and suspension behavior. Candidate replacements include polyols, soluble fibers, maltodextrin, or high-intensity sweetener systems. Polyols may create gastrointestinal tolerability issues, while high-intensity sweeteners may not replicate sucrose’s mouthfeel.

A successful reformulation would need to show equivalent dose delivery, stability, preservative performance, and patient acceptability.

Improved dose-measurement systems

The existing oral-suspension format creates opportunities for integrated packaging. A commercial product could include:

• A calibrated oral syringe.
• A bottle adapter designed for low dead volume.
• A dosing cap for institutional use.
• Child-resistant packaging with a more accessible reconstitution process.
• A ready-to-use suspension if stability permits.

Packaging can be commercially important even where the underlying formulation is similar. Pediatric medication errors often arise from confusion between milligrams and milliliters, use of household spoons, or incomplete reconstitution.

How does the VFEND tablet platform compare with the suspension and injectable forms?

Factor	Tablets	Oral suspension	Intravenous injection
Formulation complexity	Low	Moderate	High
Principal excipient risk	Lactose intolerance and manufacturing variability	Preservative, sugar, flavor, and sedimentation issues	SBECD renal exposure
Primary patient segment	Adults and patients able to swallow	Children and dysphagic patients	Hospitalized or critically ill patients
Generic competition	Strong	Moderate	More limited because of formulation complexity
Differentiation potential	Moderate	High	Very high
Main commercial barrier	Price competition	Palatability and stability	Solubilization and renal safety

Tablets are the most exposed to commodity generic competition. The suspension has more room for brand differentiation because taste, dosing accuracy, and in-use stability affect actual use. The injectable product has the greatest technical barrier because the excipient system is integral to solubility and renal risk.

What formulation patents could protect a reformulated voriconazole product?

A reformulated voriconazole product could potentially obtain protection around the formulation rather than the active ingredient. Relevant claim categories include:

• Voriconazole compositions with defined cyclodextrin ratios.
• SBECD-reduced or SBECD-free injectable solutions.
• Nanocrystalline or nanosuspension particle-size distributions.
• Taste-masked oral particles.
• Sugar-free suspensions with defined rheology.
• Preservative systems with specified pH and microbial limits.
• Ready-to-use liquid products with defined shelf life.
• Reconstitution methods and container-closure systems.
• Infusion formulations with defined dilution stability.
• Manufacturing methods that control polymorph, particle size, or dissolution.

Patent strength would depend on whether the claims cover a clinically necessary feature or merely a replaceable excipient choice. Broad claims to “voriconazole plus a pharmaceutically acceptable excipient” would face substantial validity and design-around risk. Narrower claims tied to defined concentrations, stability results, particle-size ranges, or renal-exposure reductions could have greater commercial value if supported by comparative data.

When did VFEND lose exclusivity and what is the generic-entry risk?

VFEND received US Food and Drug Administration approval in 2002.[1] The core active-ingredient and product-specific exclusivity periods have expired, and generic voriconazole products have been approved in the United States. The tablet segment therefore has high generic-entry and price-erosion risk.

The regulatory analysis differs by dosage form:

Product	Generic or follow-on risk	Commercial assessment
50 mg and 200 mg tablets	High	Standard ANDA competition and rapid price compression
40 mg/mL suspension	Moderate	Fewer products may compete because taste, reconstitution, and stability matter
200 mg intravenous product	Moderate to high	Competition exists, but injectable excipient and manufacturing requirements are more demanding
SBECD-free injectable product	Lower initial risk	Potentially differentiated 505(b)(2) opportunity, subject to clinical and regulatory requirements

An applicant pursuing the same formulation may use the abbreviated new drug application pathway if it can establish pharmaceutical equivalence and bioequivalence. A materially different injectable or oral formulation may require a 505(b)(2) application, particularly where the sponsor seeks a new clinical benefit tied to excipient changes.

What is the FDA and Orange Book status of VFEND?

VFEND is an FDA-approved drug product for invasive aspergillosis, serious infections caused by Scedosporium apiospermum and Fusarium species, and certain candidemia and deep-tissue Candida infections.[1]

The Orange Book is the controlling source for current listed patents, exclusivity, therapeutic-equivalence codes, and reference-product status.[2] For commercial planning, the relevant conclusion is that the original product is a mature reference product with established generic competition. A new sponsor should not rely on legacy active-ingredient exclusivity to support a reformulation business case.

The regulatory value of a new excipient strategy must come from one or more of the following:

• A clinically meaningful safety improvement.
• A new patient population.
• Better adherence or administration.
• Lower preparation burden.
• Reduced dosing error.
• Improved stability or supply-chain performance.
• A differentiated label supported by clinical evidence.

What generic launch scenarios exist for voriconazole?

Three launch scenarios are commercially plausible.

Standard tablet launch

A conventional tablet entrant can compete on acquisition cost, manufacturing scale, and hospital contracting. Differentiation is limited. Price erosion is likely to be strongest in the 200 mg tablet, which is widely used for adult dosing.

Oral-suspension improvement

A sponsor can compete through taste, dosing-device integration, reduced sugar, or longer after-reconstitution stability. This segment may support a higher net price than standard tablets if the product reduces administration failures or improves pediatric adherence.

Renal-safer intravenous product

A reformulated injection could command a premium if it reduces SBECD exposure and expands intravenous use in renal-impaired patients. The development program would require credible pharmacokinetic, safety, compatibility, and infusion data. A new formulation with a clinically meaningful advantage could face less direct price competition than a conventional generic.

Which companies are positioned to challenge VFEND?

Generic competition has historically come from large multisource manufacturers and injectable specialists. The relevant competitive groups include:

• Large generic companies with tablet and oral-liquid infrastructure.
• Hospital-injectable manufacturers with sterile fill-finish capacity.
• Specialty pharmaceutical companies focused on antifungal products.
• Contract development and manufacturing organizations with cyclodextrin, nanoparticle, or suspension capabilities.
• Pediatric formulation companies with taste-masking platforms.

The strongest entrant is not necessarily the company with the lowest tablet cost. It is the company able to combine regulatory execution with a differentiated formulation and reliable hospital supply.

How strong is the patent estate for an excipient-based VFEND product?

A new excipient-based voriconazole product can have a stronger commercial position than a conventional generic, but only if the formulation creates a defensible technical distinction.

A practical strength assessment is:

IP category	Relative value	Principal vulnerability
Broad excipient-combination claim	Low to moderate	Easy substitution or obviousness challenge
Defined injectable solubilization system	Moderate to high	Prior-art and enablement scrutiny
SBECD-reduced formulation with clinical renal data	High	Dependence on evidence and narrow claim scope
Taste-masked pediatric particles	Moderate	Design-around through different masking technology
Device and reconstitution system	Moderate	Separate packaging or device alternatives
Manufacturing process controlling solid state	Moderate to high	Process replication and proof of infringement

Trade secrets may be as important as patents for particle engineering, flavor systems, suspension processing, and sterile manufacturing controls. Regulatory exclusivity, if available through a new application and clinical development program, may provide a more dependable commercial barrier than broad formulation claims alone.

What revenue exposure and market opportunities matter most?

VFEND revenue exposure is concentrated in hospital antifungal treatment, specialist prescribing, and pediatric or immunocompromised populations. Generic erosion limits the value of an undifferentiated product. The higher-value opportunities are linked to avoided clinical problems:

1. Intravenous treatment when renal function limits the reference formulation.
2. Pediatric treatment where taste and dosing accuracy affect adherence.
3. Long-term oral treatment where sugar burden and administration burden matter.
4. Hospital preparation where ready-to-use presentation can reduce pharmacy labor.
5. Supply-constrained settings where an alternative sterile formulation improves reliability.

The commercial case should be based on treatment setting and formulation performance, not the aggregate voriconazole molecule market alone.

Key Takeaways

• VFEND contains voriconazole and is marketed as tablets, oral suspension, and intravenous injection.
• Tablets use conventional excipients and face the highest generic price pressure.
• The oral suspension offers differentiation through taste masking, sugar reduction, stability, and dosing-device design.
• SBECD is the central excipient issue in the intravenous product because of renal elimination and accumulation concerns.
• A lower-SBECD or SBECD-free injectable formulation has the strongest potential for clinical and commercial differentiation.
• Core VFEND exclusivity has expired, so new value must come from formulation, delivery, regulatory, or manufacturing advantages.
• Formulation patents are strongest when tied to measurable technical performance, such as renal exposure, stability, particle size, or dose uniformity.
• Generic tablets are a low-barrier opportunity; differentiated pediatric and injectable products require more development but offer better pricing potential.

FAQs

Can voriconazole tablets be reformulated without lactose?

Yes. A lactose-free tablet could use mannitol, microcrystalline cellulose, dicalcium phosphate, or another suitable diluent. The sponsor would need to demonstrate acceptable dissolution, content uniformity, stability, and bioequivalence.

Is SBECD itself a patent opportunity in voriconazole injection?

SBECD is a known pharmaceutical excipient, so composition claims directed only to its use with voriconazole may face prior-art limitations. Patent value is more likely to arise from a specific concentration range, stability profile, renal-exposure reduction, or manufacturing process.

Could a sugar-free voriconazole suspension receive separate regulatory protection?

Yes. A sugar-free suspension could support formulation claims and potentially a 505(b)(2) development strategy if it provides a meaningful pharmaceutical or clinical advantage. Regulatory protection would depend on the application and supporting data.

What is the most attractive pediatric opportunity for voriconazole?

A palatable, low-volume suspension with an integrated oral syringe is the most direct opportunity. Longer in-use stability and reduced sedimentation would improve institutional and home-use performance.

Could a ready-to-use intravenous voriconazole product replace the current vial?

Potentially, but the product would need to address chemical stability, container compatibility, particulate control, microbial assurance, storage conditions, and hospital infusion compatibility. A ready-to-use product could reduce pharmacy preparation but would carry higher packaging and stability-development costs.

References

1. U.S. Food and Drug Administration. (2024). VFEND (voriconazole) prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (1997). Guidance for industry: 180-day generic drug exclusivity under the Hatch-Waxman amendments. https://www.fda.gov

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov

5. U.S. Food and Drug Administration. (2023). Inactive ingredient database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-database-database-downloads